Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $46.00 price objective on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, January 21st.

Anavex Life Sciences Trading Up 0.9 %

NASDAQ AVXL opened at $9.91 on Tuesday. The business’s 50-day moving average price is $9.95 and its 200 day moving average price is $7.49. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $14.44. The company has a market capitalization of $840.57 million, a PE ratio of -19.06 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities analysts predict that Anavex Life Sciences will post -0.73 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its stake in Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock worth $242,000 after buying an additional 1,191 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Anavex Life Sciences by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 1,671 shares during the period. Foster Victor Wealth Advisors LLC increased its holdings in Anavex Life Sciences by 5.6% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Anavex Life Sciences by 8.5% in the second quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 2,401 shares during the period. Finally, Carnegie Investment Counsel boosted its position in shares of Anavex Life Sciences by 4.7% in the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock worth $825,000 after buying an additional 3,445 shares during the period. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.